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The growth of solid tumours is characterized not only 
by the uncontrolled proliferation of cancer cells but also by 
changes in the tumour environment that support the 
growth of the neoplastic mass and the metastatic spread 
of cancer cells to distant sites1. The formation of new 
blood vessels from pre-existing ones (angiogenesis) 
provides oxygen and nutrients to the tumour, which are 
essential for tumour growth2. A complex dynamic inter-
play exists between the expanding neoplastic mass and 
the tumour environment, which is affected by the meta-
bolic requirements of cancer cells and by their products, 
such as secreted proteins (for example, extracellular 
matrix components and proteases) and metabolites.
Upregulated glucose metabolism is a hallmark of 
invasive cancers3. In normal cells glucose is converted 
to glucose-6-phosphate and subsequently to pyruvate, 
which is then oxidized in the mitochondria to carbon 
dioxide and water; this releases 38 moles of ATP per mole 
of glucose3. However, inadequate oxygen delivery to some 
regions of tumours leads to hypoxia, which restricts oxi-
dative phosphorylation. As a consequence, hypoxic 
tumour cells shift their metabolism towards glycolysis so 
that the pyruvate generated in the first step of the process 
is reduced to lactate, generating only 2 moles of ATP per 
mole of glucose. This is a less energy-efficient process but it 
does not depend on oxygen. Furthermore, glycolysis often 
persists even after reoxygenation because the obtained 
metabolic intermediates (that is, lactate and pyruvate) can 
be used for the biosynthesis of amino acids, nucleotides 
and lipids, thus providing a selective advantage to prolif-
erating tumour cells. This explains Warburg’s observation 
of high glucose consumption and high lactate production 
in tumour tissues3–5 (known as the Warburg effect).
Oncogenic metabolism also generates an excess of 
protons and carbon dioxide, which are kept in equilib-
rium with carbonic acid by the enzyme carbonic anhy-
drase3–9. Thus, increased glucose metabolism in tumour 
cells leads to enhanced acidification of the extracellular 
milieu, which is frequently accompanied by various 
levels of hypoxia. This phenotype confers a substantial 
Darwinian growth advantage to tumour cells over normal 
cells, which undergo apoptosis in response to such an 
acidic extracellular environment3.
Tumour cells have evolved various mechanisms 
to cope with the acidic and hypoxic stress mentioned 
above. They eliminate acidic catabolites by ion trans-
porters and pumps to preserve a slightly alkaline intra-
cellular pH (pHi), which is optimal for cell proliferation 
and tumour survival3–10. Acid export leads to a reduc-
tion in the extracellular pH (pHe) to values as low as 6.0 
(the usual pHe in tumours is in the range of 6.5–7.0)
3, 
which is a salient feature of the tumour microenviron-
ment3–9. As well as triggering the overexpression of many 
proteins involved in glucose metabolism — such as the 
glucose transporter GLUT1 (also known as SLC2A1) 
and pH-regulating proteins such as carbonic anhydrase 9 
(CA9)3,4,10 — hypoxia also constitutes a detrimental 
feature for radiotherapy, as oxygen is needed to oxidize the 
radiation-induced DNA free radicals that subsequently 
lead to tumour cell death4.
pH homeostasis in any cell type is a complicated 
process that involves many proteins and buffer systems4. 
In tumour cells, these processes are even more complex 
owing to the internal compartment being slightly more 
alkaline (pH 7.4 or more) and the external compartment 
being more acidic than in normal cells4–9. A variation 
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Warburg effect
The ability of cancer cells to 
predominantly produce energy 
by a high rate of glycolysis 
followed by lactic acid 
fermentation in the cytosol, 
rather than by glycolysis 
followed by oxidation of 
pyruvate in the mitochondria, 
as most normal cells do.
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Abstract | The high metabolic rate of tumours often leads to acidosis and hypoxia in poorly 
perfused regions. Tumour cells have thus evolved the ability to function in a more acidic 
environment than normal cells. Key pH regulators in tumour cells include: isoforms 2, 9 and 
12 of carbonic anhydrase, isoforms of anion exchangers, Na+/HCO
3
– co-transporters, Na+/H+ 
exchangers, monocarboxylate transporters and the vacuolar ATPase. Both small molecules 
and antibodies targeting these pH regulators are currently at various stages of clinical 
development. These antitumour mechanisms are not exploited by the classical cancer drugs 
and therefore represent a new anticancer drug discovery strategy.
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in the pHi/pHe ratio as low as 0.1 pH units may disrupt 
important biochemical and/or biological processes 
such as ATP synthesis, enzyme function and the prolif-
eration, migration, invasion and metastasis of tumour 
cells5; consequently, a tight regulation of these processes 
has evolved5–9. Changes in the pHi as low as 0.1–0.2 pH 
units also trigger mechanisms of alternative splicing of 
extracellular matrix components that generate different 
isoforms of tenascin and fibronectin, which are typical 
of tumour cells and not normal cells11,12. These alterna-
tively spliced proteins are not involved in pH regulation 
but they may constitute a novel antitumour mechanism 
(BOX 1).
Several sophisticated molecular mechanisms are 
responsible for maintaining the alkaline pHi and the 
acidic pHe in tumour cells
5–10. These include proteins that 
import weak bases (such as the HCO3
– ion) into the cells 
and proteins that export the weak acids generated during 
metabolism — such as carbon dioxide, carbonic acid or 
lactic acid — out of the cells4. In addition, H+ ions are 
directly extruded from the cells, either in exchange for 
other cations (such as Na+) or by means of the vacuolar 
ATPase (V-ATPase)5–9,13,14.
The main players involved in the regulation of tumour 
pH are shown in FIG. 1 and include: CA2, CA9 and CA12 
(REFS 15–17); V-ATPase18; the anion exchangers AE1 
(also known as SLC4A1), AE2 (also known as SLC4A2) 
and AE3 (also known as SLC4A3)19,20; Na+/HCO3
– 
co-transporters (NBCs)14; electroneutral Na+-driven Cl–/
HCO3
– exchanger (NDCBE; also known as SLC4A8)14; 
Na+/H+ exchanger 1 (NHE1; also known as SLC9A1)14; and 
the monocarboxylate transporters MCT1, MCT2, MCT3 
and MCT4 (REFS 21,22). Many of these proteins exist as 
multiple isoforms, which represents a complication from 
the medicinal chemistry viewpoint, as a good drug should 
target only the desired isoform. Carbonic anhydrases15,16, 
anion exchangers and MCTs all have several isoforms and 
not all of these are associated with tumours14–23.
There are various approaches for targeting one or 
more of these proteins to restore both pHi and pHe in 
cancer cells towards normal values and halt tumour 
growth. This constitutes an antitumour mechanism 
that has not yet been exploited by any of the classical 
anticancer drugs. Proof-of-concept studies that were 
performed during the past few years have led to the 
validation of some of these proteins as new anticancer 
drug targets. This Review discusses recent advances in 
the development of pharmaceutical agents that interfere 
with pH regulation in tumours, with a special focus on 
carbonic anhydrases.
Tumour-associated carbonic anhydrases
α-carbonic anhydrases (EC 4.2.1.1) are metalloenzymes 
that are widespread in higher vertebrates, including 
humans15,16. So far, 16 isoforms of carbonic anhydrase 
have been characterized in mammals (15 in humans; 
CA15 is not expressed in primates), which differ in 
their subcellular localization, catalytic activity and 
susceptibility to different classes of inhibitors. There 
are cytosolic isozymes (CA1, CA2, CA3, CA7 and 
CA13), membrane-bound isozymes (CA4, CA9, CA12, 
CA14 and CA15), mitochondrial isozymes (CA5A 
and CA5B) and secreted isozymes (CA6). Three acata-
lytic isoforms — CA8, CA10 and CA11 — called carbonic 
anhydrase-related proteins have also been identified24,25.
Most carbonic anhydrases are very efficient catalysts 
for the reversible hydration of carbon dioxide to bicar-
bonate and protons (CO2 + H2O ↔ HCO3
– + H+), which 
is a vital reaction in most organisms15,16. The HCO3
–– 
carbonic acid system is the main buffer of pH in all living 
cells15,16. Carbon dioxide is generated in high amounts 
as the final product of oxidative phosphorylation, and 
is immediately converted to HCO3
– by carbonic anhy-
drases. The uncatalysed hydration reaction of this gas 
is too slow to meet the physiological needs of the cell, 
which is why so many carbonic anhydrase isoforms 
have evolved15,16. In mammals carbonic anhydrases are 
involved in processes such as respiration and acid–base 
regulation, electrolyte secretion, bone resorption and 
calcification, and in biosynthetic reactions that require 
HCO3
– as a substrate (such as lipogenesis, gluconeogene-
sis and ureagenesis), whereas in plants and bacteria these 
enzymes are also involved in photosynthesis and carbon 
dioxide-fixation mechanisms15,16,26. Two carbonic anhy-
drase isozymes (CA9 and CA12) are overexpressed in 
many tumours, and are associated with cancer progression 
and response to therapy15–17,27,28.
CA9 is expressed in the stomach and peritoneal 
lining, but it is ectopically induced and overexpressed in 
several types of solid tumours, predominantly owing to 
strong transcriptional activation of hypoxia-inducible 
transcription factor 1 (HIF1)12,15–17,28,29. Interestingly, 
CA9 is the most strongly overexpressed gene in response 
to hypoxia in human cancer cells28,30, and it is also the 
most active isoform of carbonic anhydrase for the 
car bon dioxide hydration reaction29,31. The X-ray crystal 
structure of CA9 reveals that it is a dimeric enzyme32, 
unlike all other carbonic anhydrase isoforms known so 
far, which are monomeric. Like CA9, CA12 is a trans-
membrane isoform with an extracellular active site27 
but it has lower catalytic activity than CA9 (REFS 15,33). 
CA12 is also expressed in many tumours but it is 
more diffuse in some healthy tissues27. Given that 
carbonic anhydrases are considerably simple enzymes 
that are biochemically well characterized and have a 
multitude of known inhibitors15,16 (FIG. 2), their potential 
as anticancer drug targets is very attractive.
Sulphonamides as carbonic anhydrase inhibitors. 
Primary sulphonamides, sulphamates and sulphamides 
act as carbonic anhydrase inhibitors (CAIs) by binding 
to the catalytic Zn2+ ion in the active site of the enzyme 
and blocking its function15,16. Some of these compounds 
inhibit both CA9 and CA12 (REFS 15,16,33–37). Many 
such compounds were specifically designed for tar-
geting these tumour-associated isoforms of carbonic 
anhydrase38. The main approaches for developing such 
compounds are listed below.
One approach is the addition of fluorescent tags to 
generate fluorescent sulphonamides (compound 1; FIG. 2), 
which are used for imaging purposes and for determin-
ing the role of CA9 in tumour acidification28,39. Another 
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approach is the addition of a positive or negative charge to 
sulphonamide and sulphamate CAIs (compound 2; FIG. 2)
so that they are unable to cross plasma membranes and 
thus selectively inhibit extracellular carbonic anhydrases, 
which include CA9 and CA12 (REF. 40). Such compounds 
are completely different from the classical sulphona-
mide inhibitor acetazolamide, (compound 3; FIG. 2) 
which is a promiscuous, potent inhibitor of most car-
bonic anhydrase isoforms. Acetazolamide has been an 
important lead for generating other inhibitors with a 
better selectivity profile (compounds 4 and 5; FIG. 2)41, 
and has led to the development of compounds that are 
activated by hypoxia and exploit the reducing condi-
tions of hypoxic tumours to convert an inactive prodrug 
Box 1 | Tumour-associated splice isoforms regulated by intracellular pH
Elevation of the intracellular pH (pH
i
)
 
in tumour cells leads to the generation of alternatively spliced extracellular matrix 
components, which may serve as targets for antibody-based cancer therapy11,12. The insertion or omission of extra domains 
in tenascin C illustrates this process.
Tenascins are a family of four extracellular matrix glycoproteins that are found in vertebrates. They are typically present in  
many different connective tissues. Tenascins contribute to matrix structure and influence the behaviour of cells that are  
in contact with the extracellular matrix. Several isoforms of tenascin C can be generated as a result of different patterns of 
alternative splicing in the region between domains A1 and D (see figure). In normal tissues and at pH
i
 values of around 7.0, 
cells typically produce the ‘small’ tenascin C splice isoform, which does not include domains A1 to D. When cells are 
artificially exposed to basic pH values — for example, in cell culture experiments, fetal tissues (which typically have basic 
pH values of around 7.4–7.5 units) or in aggressive forms of cancer — changes of 0.2–0.3 pH units in the pH
i
 value lead to  
a complete switch towards the formation of the ‘large’ tenascin C splice isoform, which includes domains A1 to D11,12. 
Interestingly, tenascin C splice isoforms are commonly found in the tumour stroma and/or around tumour blood vessels92–98 
and serve as markers of angiogenesis99. The regulation of alternative splicing of tenascin C is complicated by the 
observation that the extra domain C displays a more restricted pattern of expression than the other domains between  
A1 and D100,101. However, whenever this domain is inserted into the tenascin C molecule (for example, in high-grade 
astrocytomas), it tends to accumulate around neovascular tumour structures100–102. The A1 domain of tenascin C is the 
target of the F16 antibody, whereas the 81C6 antibody recognizes domain D.
Similarly to tenascin C, other components of the extracellular matrix undergo alternative splicing, and the corresponding 
extra domains represent some of the best characterized markers of tumour angiogenesis and the tumour stroma. The 
alternatively spliced domains extra domain A (EDA) and extra domain B (EDB) of fibronectin, which are targeted by the F8 
and L19 antibodies, respectively, exhibit a high level of conservation among species and are virtually undetectable in normal 
tissues; however, they are abundantly expressed in the stroma and neovasculature of most aggressive types of human 
cancers96,102–110. Similarly, systematic chemical proteomics studies107,111–113 have recently shown that another component of 
the extracellular matrix, periostin, exists in several splice isoforms that are abundantly found in most types of cancers111–114. 
Compound Generic/ 
trade name
Product category Indications Highest 
phase
Organization
Splice isoforms of tenascin C
131I-81C6 Neuradiab Radiolabelled antibody Brain cancer Phase III Bradmer 
Pharmaceuticals
F16–IL-2 Teleukin Antibody–cytokine fusion protein Breast cancer, 
lung cancer
Phase II Philogen
131I-F16 Tenarad Radiolabelled antibody Hodgkin’s 
lymphoma
Phase II Philogen
124I-F16 Tenapet Radiolabelled antibody Various tumours Phase II Philogen
Splice isoforms of fibronectin
L19–IL-2 Darleukin Antibody–cytokine fusion protein Melanoma Phase II Philogen
131I-L19 Radretumab Radiolabelled antibody Brain metastases Phase II Philogen
L19–TNF Fibromun Antibody–cytokine fusion protein Melanoma (ILP) Phase II Philogen
huBC1–IL-12 AS1409 Antibody–cytokine fusion protein Melanoma Phase I/II Antisoma
F8–IL-10 Dekavil Antibody–cytokine fusion protein Arthritis Phase I Philogen
IL-2, interleukin-2; ILP, isolated limb perfusion; TNF, tumour necrosis factor.
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Orthotopic tumours
Tumours that occur at the 
normal place in the body in  
an animal model of cancer  
(for example, mouse orthotopic 
mammary tumours develop  
in the mammary gland of  
the animal).
into an active CAI (compound 6; FIG. 2)40. The addition 
of sugar moieties to CAIs — leading to the formation of 
sugar-containing sulphonamides, sulphamates and 
sulphamides that are highly hydrophilic and unable to 
cross membranes easily — is another approach; these 
sugar-containing sulphonamides possess an enhanced 
selectivity for extracellular carbonic anhydrases such as 
CA9 and CA12 (compounds 7 and 8; FIG. 2)15,16,40. Other 
approaches for targeting these enzymes involve inves-
tigating different chemotypes of sulphonamides42,43 or 
using nanoparticles to design CAIs44.
The first study linking the inhibition of CA9 with 
tumour shrinkage used the fluorescent sulphonamide 
(compound 1, n=1) and the cationic compound 2 (REF 28). 
This study showed that these derivatives — which have a 
high affinity for CA9 and CA12 (inhibition constants of 
5–24 nM)36 — are useful probes for hypoxic tumours28,45,46. 
Compound 1 (n=1) inhibits CA9 only under hypoxic con-
ditions in vivo, in cell cultures or in animals with trans-
planted tumours. Although the biochemical rationale for 
this phenomenon is not yet understood, these properties 
may be exploited in the design of diagnostic tools for 
imaging hypoxic tumours.
It is interesting to note that in tumour cell cultures 
that were treated with compound 1 (n=1 or n=2) or 
compound 2, the acidic pHe was reversed towards more 
normal pH values, which was undoubtedly due to the 
inhibition of the tumour-associated carbonic anhy-
drases28,45,46. Compound 1 (n=1), with a high affinity for 
CA9, was shown via non-invasive fluorescent imaging, 
to bind to cells only when the CA9 protein was expressed 
and when cells were hypoxic, in an in vivo model of 
cancer46. Fluorescently labelled sulphonamides may 
therefore provide a powerful tool for visualizing hypoxia 
responses in solid tumours and could be used to select 
patients for CA9-directed therapies46.
An interesting study reported that in hypoxic 
LS174Tr tumour cells that overexpress both CA9 and 
CA12, it was possible to genetically silence one or both 
carbonic anhydrase isoforms47. Genetic silencing of CA9 
alone caused a 40% reduction in xenograft tumour 
volume and led to the overexpression of CA12. However, 
these cells were kept at an artificially low HCO3
– concen-
tration, and this observation has not been reproduced45,48. 
Genetic silencing of both CA9 and CA12 led to an 85% 
reduction in tumour growth, which suggests that CA9 
and CA12 are major tumour prosurvival pH-regulating 
enzymes47.
Membrane-impermeable sulphonamide derivatives 
(compounds 4 and 5), which are based on the acetazola-
mide scaffold to which either fluorescein–carboxylic acid 
or albumin-binding moieties were attached, suppressed 
tumour growth in mice with xenografts of a clear-cell 
renal cell carcinoma cell line when they were admin-
istered alone or in combination with other anticancer 
drugs41. These data were the first to demonstrate in vivo 
the potential of sulphonamides (or related agents acting 
on CA9 or CA12) as alternative anticancer drugs15,16,41. 
Since then, potent bis-sulphonamide CA9 inhibitors 
that accumulate in colorectal adenocarcinoma xeno-
grafted tumour sections in mice have also been identi-
fied in a library of one million DNA-encoded chemical 
compounds41.
Interestingly, in a mouse model of breast cancer the 
overexpression of CA9 in hypoxic conditions led to 
the formation of spontaneous lung metastasis48. Treatment 
of the mice harbouring such orthotopic tumours with 
compound 1 (n=2), at a dose of 75 mg per kg, led to 
the regression of orthotopic mammary tumours and 
inhibited the formation of lung metastases48. However, 
even stronger effects were observed with the ureido-
sulphonamide inhibitor (compound 9; FIG. 2), a CA9 
inhibitor with low nanomolar potency, which substan-
tially inhibited both the growth of primary tumours 
and metastases in the same animal model, at doses of 
30–45 mg per kg47,50. Thus, sulphonamide CAIs that tar-
get CA9 seem to be effective at inhibiting the growth of 
both the primary tumour and metastases, at least in this 
animal model47,49. Some of these compounds are in 
advanced preclinical evaluation47,50 (TABLE 1). It has also 
been observed that combining CA9 inhibition (via sul-
phonamide or sulphamate compounds) with tumour 
irradiation has a synergistic antitumour effect in HT29 
carcinoma cells xenografted in mice51.
Figure 1 | Proteins involved in pH regulation within a tumour cell. The figure  
shows various proteins that are involved in regulating pH within tumours, including: 
monocarboxylate transporters (MCTs), which transport lactic acid and other 
monocarboxylates formed by the glycolytic degradation of glucose; Na+/H+ exchangers 
(NHEs); the plasma membrane proton pump vacuolar ATPase (V-ATPase); anion 
exchangers (AEs); Na+/HCO
3
– co-transporters (NBCs); and carbonic anhydrases  
(CA2, CA9 and/or CA12). The glucose transporter GLUT1 (which is upregulated in most 
tumours) transports glucose into tumour cells. The intracellular tumour pH (pH
i
) is slightly 
alkaline (pH 7.2–7.4), whereas the extracellular pH (pH
e
) is slightly acidic (pH 6.5–7.0).  
BT, HCO
3
– transporter; CBP, cyclic AMP-responsive element-binding (CREB) protein;  
HIF1, hypoxia-inducible transcription factor 1; p300, histone acetyltransferase p300.
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Alternative CAIs. Coumarins and thiocoumarins were 
only recently discovered to have carbonic anhydrase-
inhibiting properties, and their mechanism of inhibi-
tion has subsequently been deciphered42,43. The nat ural 
product 6-(1S-hydroxy-3-methylbutyl)-7- methoxy- 
2H-chromen-2-one (compound 10; FIG. 2) is hydrolysed 
within the carbonic anhydrase active site, leading to the 
formation of the 2-hydroxycinnamic acids (compound 
11; FIG. 2), which represent the de facto enzyme inhibitor. 
This new class of CAIs binds to carbonic anhydrase in its 
hydrolysed form at the entrance of the active site, and does 
not interact with the metal ion, thus constituting a class of 
CAIs with a new mechanism of action42,43. 
As well as the natural coumarin compound (com-
pound 10), compounds 12 and 13 (GC-205) (FIG. 2) 
that were discovered thereafter have been shown to be 
potent and selective inhibitors against some human 
isoforms of carbonic anhydrase. Compounds such as 
12 and GC-205 are selective CA9 and CA12 inhibitors 
with a low nanomolar potency that do not substantially 
inhibit the off-target isoforms CA1 and CA2 (REFS 51,52). 
Furthermore, like the sulphonamide CAIs, GC-205 was 
recently shown to inhibit the growth of primary tumours 
and metastases in an animal model of breast cancer47 and 
is in advanced preclinical evaluation as an anti cancer 
and antimetastasis agent47 (TABLE 1).
It has been demonstrated that the protein tyrosine 
kinase (PTK) inhibitors that are in clinical use53 — imatinib 
(Gleevec; Novartis (compound 14; FIG. 2)) and nilotinib 
(Tasigna; Novartis (compound 15; FIG. 2)) — also inhibit 
some physiologically relevant carbonic anhydrase iso-
forms, albeit less efficiently than sulphonamides and cou-
marins54. Indeed, imatinib and nilotinib can inhibit CA1, 
CA2, CA9 and CA12 at nanomolar concentrations; how-
ever, their mechanism of inhibition is not yet understood 
as X-ray crystal structures for the adducts of any carbonic 
anhydrase isozymes with these compounds have not been 
obtained so far54. Nonetheless, this is an important finding 
 
 
 
 
 
 
Figure 2 | Carbonic anhydrase inhibitors of the sulphonamide  
type and alternative chemotypes. Fluorescent sulphonamides  
(compound 1, n=1, n=2) and compound 2 were used in the 
proof-of-concept study showing carbonic anhydrase 9 (CA9)-mediated 
tumour acidification28. Acetazolamide (compound 3) is a classical 
carbonic anhydrase inhibitor, and was used as a basis for the 
development of several compounds with carbonic anhydrase-inhibiting  
properties (compounds 4, 5, 6). Sugar sulphonamides (compound 7, 8),  
as well as the ureido derivative (compound 9) showed potent in vitro 
and in vivo CA9 inhibition and antitumour effects48. Coumarins 
(compounds 10, 11, 12, 13) and the protein tyrosine kinase inhibitors 
imatinib (compound 14) and nilotinib (compound 15) belong to the 
alternative chemotypes that inhibit tumour-associated carbonic 
anhydrases. 
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 that may explain their potent antitumour effects in malig-
nancies such as gastrointestinal stromal tumours, which 
overexpress CA2 (REF. 55). A synergy between PTK inhi-
bition and the inhibition of cancer-associated carbonic 
anhydrase isoforms could explain the potent therapeu-
tic effect observed with imatinib and nilotinib in vari-
ous types of metastatic cancer. Studies in experimental 
models of cancer combining a selective PTK inhibitor 
and a selective CAI would be required to investigate this 
hypothesis.
Monoclonal antibodies may represent the most con-
venient avenue for the selective inhibition of CA9 and 
CA12 (REFS 56,57). Compared to rodent antibodies, chi-
meric and humanized antibodies are less immunogenic 
in humans58, can be generated easily and with excellent 
specificity59, and do not spontaneously cross the cell 
membrane60.
M75 is a monoclonal antibody with a high specificity 
for CA9 that targets the proteoglycan domain of the 
enzyme61. It has been used in immunohistochemical 
and western blot studies for identifying CA9 in various 
types of tumours, and a radiolabelled form of this anti-
body is used for imaging tumours via positron emission 
tomography (PET). The biological distribution of this 
radiolabelled monoclonal antibody in nude mice with 
HT-29 human colorectal carcinoma xenografts that over-
expressed CA9 in hypoxic conditions demonstrated that 
the radioactivity accumulated only in the tumour61. Thus, 
monoclonal antibodies labelled with various PET tracers 
may be used successfully for imaging hypoxic tumours 
that overexpress CA9.
WX-G250 is another CA9-specific chimeric mono-
clonal antibody that is in Phase III clinical trials as an 
adjuvant therapy for the treatment of non-metastasized 
renal cell carcinoma in patients who are at a high risk 
of recurrence after resection of the primary tumour62. 
Phase III trials are also underway at Wilex for the treat-
ment of metastatic renal cell carcinoma in combination 
with interleukin-2 or interferon-α62. Antibody binding to 
CA9 on tumour cells triggers antibody-dependent cell-
ular cytotoxicity, an immune reaction in which effector 
cells such as natural killer cells are engaged in a binding 
interaction via their Fcγ receptors and are activated to 
release toxic granuli60. Recently, CA12-specific mono-
clonal antibodies have been generated and characterized. 
Such monoclonal antibodies inhibit the enzymatic activity 
of CA12 in the low nanomolar or subnanomolar range 
and also inhibit tumour growth56.
Somewhat surprisingly, considerable differences 
in tumour-targeting performance have been observed 
among different CA9-specific antibodies, with the 
approaches developed by the Boerman group resulting 
in some of the highest tumour uptake values ever 
reported in the field of antibody-based tumour target-
ing63,64. The observation that pre-targeting strategies 
(that is, the sequential administration of a bi-specific 
antibody, which is specific to CA9 and a metal chela-
tor, followed by the intravenous injection of the complex 
of the metal chelator with a suitable radionuclide) lead 
to an extremely high and rapid uptake of radioactivity 
in mouse models of renal cell carcinoma64 suggests that 
small high-affinity ligands may be distributed more 
rapidly into tumour tissues than antibodies.
Bayer, MorphoSys and Seattle Genetics have 
advanced a CA9-specific antibody, coupled to the potent 
cytotoxic drug auristatin, to Phase I clinical trials in 
patients with various types of solid cancer (TABLE 1). In 
the future, it may be possible to bypass antibodies with 
high-affinity CA9 ligands (for example, sulphonamide 
derivatives), which could serve as modular targeting 
agents for pharmacodelivery applications. These inno-
vative biomedical strategies bear certain analogies to the 
successful use of folate derivatives for targeting tumours 
overexpressing folate receptors, as pioneered by the Low 
group65. Indeed, many studies have shown that anti-
bodies are restricted in their ability to access the most 
hypoxic and poorly vascularized regions of tumours63–65. 
Such problems are not normally encountered with small 
molecules such as CA9 and CA12 inhibitors15.
V-ATPase inhibitors and proton pump inhibitors
V-ATPase is an ATP-dependent proton pump that is 
involved in the acidification of intracellular compart-
ments and the extrusion of protons through the cytoplas-
mic membrane of the cell18,66,67. This enzyme has a crucial 
role in regulating the pH of normal cells and tumour 
cells. It consists of multiple subunits (formed from sev-
eral multisubunit proteins) with both cytosolic and trans-
membrane domains18,66,67. In addition to proton transfer 
processes, V-ATPase is involved in a host of physiological 
Table 1 | Carbonic anhydrase 9 inhibitors in clinical development or in use 
Compound Generic/trade name Product category Indications Highest phase Organization
cG250 Girentuximab Chimeric antibody Kidney cancer Phase III Wilex
124I-cG250 124I-girentuximab Radiolabelled antibody Cancer imaging Phase III Wilex
3ee9–MMAE BAY-79-4620 Antibody–drug conjugate Solid tumours Phase I Bayer/MorphoSys
Imatinib Gleevec PTK inhibitor and/or CAI GISTs, CML In clinical use Novartis
Nilotinib Tasigna PTK inhibitor and/or CAI GISTs, CML In clinical use Novartis
U-104 Not available Sulphonamide CAI Solid tumours and/or 
metastases
Preclinical MetaSignal Therapeutics
GC-205 Not available Coumarin CAI Solid tumours and/or 
metastases
Preclinical MetaSignal Therapeutics
CAI, carbonic anhydrase inhibitor; CML, chronic myeloid leukaemia; GIST, gastrointestinal stromal tumours; MMAE, monomethyl auristatin E; PTK, protein tyrosine kinase.
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Metabolon
A temporary structural–
functional complex formed 
between sequential enzymes 
or proteins of a metabolic 
pathway. It is held together by 
non-covalent interactions and 
structural elements of the cell, 
such as integral membrane 
proteins and proteins of the 
cytoskeleton.
and pathological processes, such as endocytosis, intracell-
ular trafficking and the acidification of endosomes, as 
well as the creation of an appropriate microenvironment 
for protein transport18. It is therefore not improbable that 
V-ATPase also participates in the regulation of pHe
66,67.
There are various classes of V-ATPase inhibitors, such 
as the macrocyclic antibiotics bafilomycin A and con-
canamycin A, a large series of benzolactone enamides 
incorporating a salicylic acid scaffold, the macro cyclic 
antibiotic archazolid and some free radical indolyls18, 
but all of these inhibitors are highly toxic and difficult 
to use as tools for understanding the role of V-ATPase 
in tumorigenesis. However, one study has suggested that 
bafilomycin A retards the growth of pancreatic xenograft 
tumours68.
The similarity between V-ATPase and H+,K+ ATPase, 
the enzyme involved in proton secretion in the stomach, 
prompted the investigation of proton pump inhibitors 
(PPIs) of the omeprazole type for inhibiting V-ATPase66,69. 
Such compounds — including omeprazole, pantopra-
zole, lansoprazole and rabeprazole (compounds 16, 
17, 18 and 19; FIG. 3), among others — are widely used 
clinically as antacids and are prodrugs that require acid-
ity to be activated66,67,69,70. In an acidic environment they 
undergo a transformation that leads to the formation of a 
sulphenamide, which reacts with cysteine residues of the 
proton pump and results in its inactivation70. PPIs may 
also target the acidic (hypoxic) tumour mass, where they 
are metabolized as in the stomach and block the forma-
tion and trafficking of protons6,66. Proton pump inhibi-
tion was shown to trigger rapid cell death as a result of 
intracellular acidification, caspase activation and early 
accumulation of reactive oxygen species in tumour 
cells66. Many human tumours — including melano-
mas, osteosarcomas, lymphomas and various adeno-
carcinomas — were shown to be responsive to PPIs6,66. 
Metastatic tumours seemed to be even more respon-
sive to PPIs as they are generally more acidic than most 
primary tumours66,69.
Two clinical trials are testing the effectiveness of 
PPIs in patients with chemosensitizing melanoma and 
osteosarcoma66. Indeed, tumour acidity represents a very 
potent mechanism of chemoresistance71, as most cyto-
toxic agents are weak bases that are quickly protonated 
outside the cell and prevented from reaching specific 
cell ular targets. Compounds that show enhanced uptake 
by hypoxic tumours (with a pHe value in the range of 
6.5–7.0) are those that possess a logarithmic acid dis-
sociation constant (pKa) in the range of 5–6 — the car-
boxylic acids71. Further studies will determine whether 
PPIs represent a new class of antitumour agents with a 
low level of systemic toxicity compared with standard 
chemotherapeutic  agents.
Interference with HCO3
– transport
HCO3
– transporters facilitate the movement of the 
membrane-impermeant HCO3
– ion across biological 
membranes72. They are phylogenetically clustered into 
three classes: electroneutral Cl–/HCO3
– exchangers of the 
solute carrier 4A (SLC4A) family, the anion exchangers; 
the NBC family of Na+/HCO3
– co-transporters; and 
anion transporters of the SLC26 family19,20,72.
Inhibiting the anion exchangers. The anion exchanger 
family is composed of three isoforms: AE1, AE2 and 
AE3. Human AE1 is formed from a 43 kDa amino- 
terminal domain, a 55  kDa membrane-spanning 
domain (which is responsible for Cl–/HCO3
– exchange 
activity) and a 33 kDa cytoplasmic carboxy-terminal 
domain that contains the binding site for CA2 (REF. 72). 
AE2 is the most widely expressed isoform, whereas 
AE3 is predominantly expressed in excitable tissues 
and throughout the gastrointestinal tract72. The physical 
and functional interactions between these HCO3
– trans-
porters and the various carbonic anhydrase isoforms72 
suggest that they could form a complex. This has been 
demonstrated for the AE1–CA2 metabolon73. In this 
complex, carbonic anhydrases supply the HCO3
– sub-
strate for transport (by catalysing their physiological 
reaction: the hydration of CO2 to HCO3
– and H+), 
whereas the HCO3
– transporter translocates the mem-
brane-impermeant HCO3
– into or out of the cell72,73; 
however, carbonic anhydrases may also remove HCO3
– 
by catalysing the reverse reaction.
CA9 has been demonstrated to form a metabolon 
with isoform AE2 (REF. 74). The concerted action of the 
enzyme and the anion exchanger may lead to the high 
pHi that is characteristic of tumour cells and to the acidifi-
cation of the pHe, through the shuttling of HCO3
– into or 
out of the cell. This mechanism may also explain why an 
intracellular isoform (CA2) and two extracellular isoforms 
(CA9 and CA12) are involved in pH regulation in cancer 
cells15,72. 4,4′-Diisothiocyano-2,2′-stilbenedisulphonic 
acid (DIDS) (compound 20; FIG. 4)and structurally related 
stilbenes act as inhibitors of anion exchangers, but they 
also indiscriminately inhibit other HCO3
– transporters75. 
These compounds initially block the anion exchangers 
reversibly and later block them irreversibly75. DIDS has 
antitumour activity and it induces apoptosis in HA22T 
hepatocellular carcinoma cells overexpressing AE2 
(REF. 76).
Another potent CA9 and CA12 inhibitor, celecoxib 
(Celebrex; Pfizer (compound 21; FIG. 4))15, and several 
other potent sulphonamide CAIs such as compound 22 
(FIG. 4) substantially inhibited the Cl–/HCO3
– exchange 
Figure 3 | Proton pump inhibitors in clinical use. Omeprazole (compound 16), 
pantoprazole (compound 17), lansoprazole (compound 18) and rabeprazole 
(compound 19) are used in the treatment of gastric ulcers but have also shown 
promising antitumour effects in animal models of cancer by a mechanism of action  
that is not yet completely understood66.
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activity of AE1, with EC50 (the effector concentration 
for half-maximum response) values in the range of 
0.22–2.8 μM. It was evident that bulkier compounds 
such as compound 22 inhibited AE1 more potently 
than sulphonamides incorporating less bulky moie-
ties. The maximum inhibition achieved, using 40 μM 
of each compound, was only 22–53% of AE1 transport 
activity, possibly because the assays were performed in 
the presence of competing substrates. In the Cl–/HCO3
– 
exchange assays, which depend on functional carbonic 
anhydrase to produce the transport substrate, 40 μM 
of celecoxib inhibited AE1 by 62%. Thus, some sul-
phonamide CAIs, including the clinically used analgesic 
celecoxib, can inhibit AE1-mediated HCO3
– transport at 
clinically significant concentrations20. Celecoxib shows 
substantial antitumour activity, possibly owing to its 
cyclooxygenase 2-, CA9- and CA12-inhibiting proper-
ties, although other mechanisms of action may also be 
involved77,78. Compounds that specifically inhibit anion 
exchangers and do not interfere with other enzymes or 
transport proteins are not yet available.
Inhibiting other HCO3
– exchangers. The NBC family 
of co-transporters is composed of: electrogenic Na+/
HCO3
– co-transporter 1 (NBC1; also known as 
SLC4A4), electrogenic NBC4 (also known as SLC4A5), 
electroneutral NBC3 (also known as SLC4A7), NDCBE 
and the Na+-driven Cl–/HCO3
– exchanger NCBE (also 
known as SLC4A10). NBCs have a widespread tissue 
distribution72. These co-transporters facilitate the trans-
port of Na+ and HCO3
– across the plasma membrane 
with an electroneutral or electrogenic (two or three 
HCO3
– per Na+) mechanism72. NBC3 is an electroneu-
tral co-transporter that is involved in the regulation of 
pHi in the heart, skeletal muscle and kidney. Like other 
HCO3
– transporters, a region in the C terminus of NBC3 
(D1135–D1136) binds to CA2, and this interaction was 
shown to be essential for maximal HCO3
– transport72. 
NBC1 is an electrogenic co-transporter, which operates 
with either a 3:1 or 2:1 HCO3
–:Na+ stoichiometry. NBC1 
mediates HCO3
– efflux from the cell to the blood, and 
normally works with a stoichiometry of three HCO3
– per 
Na+. CA4 and NBC1 have been shown to colocalize in 
the mammalian kidney, pancreas and heart19.
DIDS is an inhibitor of these transporters, but owing 
to its toxicity it cannot be used as a therapeutic agent79. 
Another inhibitor of these HCO3
– transporters — S3705 
— has been reported and evaluated for the inhibition 
of proliferation and apoptosis of the human cholangio-
carcinoma cell lines HUH-28 and Mz-ChA-180; the 
structure of S3705, however, has not been disclosed. The 
pHi of the treated cells was shown to decrease following 
inhibition with S3705. Incubation of HUH-28 cells with 
cariporide (compound 24; FIG. 4) and/or S3705 reduced 
cell proliferation and induced apoptosis80. The same two 
agents (cariporide and S3705) were investigated for their 
effects on the toxicity of the anticancer drug melphalan 
in two human breast cancer cell lines (MDA-MB231 
and MCF7)81, but the effects of the two drugs on pHe 
were too small to warrant clinical studies. Like anion 
exchangers, there is a lack of selective ligands for these 
other HCO3
– exchangers. 
Inhibitors of Na+/H+ exchanger 1
NHE1 is expressed in cells all over the body and is one of 
the crucial proteins involved in pH regulation5,6. NHE1 
is involved in tumorigenesis, as deletion of this protein 
drastically reduces tumour growth82. The same effects 
have been observed using pharmacological inhibitors6,83 
such as amiloride or cariporide84 (compound 23 and 24; 
FIG. 4). There are numerous NHE1 inhibitors that are 
structurally related to amiloride and cariporide, all of 
them possessing the pyrazine–acylguanidine scaffold 
that is present in amiloride along with various other 
substituents to the pyrazine ring84.
The inhibition of NHE1 is useful not only for the 
management of tumours but also for the treatment of 
acute renal failure. Cardioprotective and cerebroprotec-
tive effects of NHE1 have also been reported84. However, 
owing to the diffuse presence of NHE1 in many tissues 
and its fundamental role in crucial physiological pro-
cesses, there is a potential risk of life-threatening side 
Figure 4 | Compounds interfering with Na+/HCO3
– co-transporters, anion exchangers and Na+/H+ exchanger 1. 
4,4′-Diisothiocyano-2,2′-stilbenedisulphonic acid (DIDS) (compound 20), celecoxib (compound 21) and structurally 
related sulphonamides — such as compound 22, amiloride (compound 23) and cariporide (compound 24), as well as the 
stilbene derivative α-cyano-4-hydroxycynnamic acid (compound 25) or the organomercuric compound 4-chloromer-
curibenzene sulphonic acid (compound 26) — interfere with several proteins that are involved in the transport of HCO
3
–, 
such as the anion exchangers, Na+/HCO
3
– co-transporters and Na+/H+ exchanger 1.
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effects associated with this class of agents. In fact, Sanofi 
has stopped the clinical development of cariporide owing 
to the unexpected incidence of stroke in a large Phase III 
clinical trial85. To exploit the benefits of NHE1 inhibition 
in the treatment of cancer, it would be crucial to develop 
agents that selectively target NHE1 in tumours and do 
not target the enzyme in healthy tissues.
Monocarboxylate transporter inhibitors
There are at least nine different isoforms of proteins that 
are involved in the transport of monocarboxylates into 
and out of cells, but MCT1, MCT2, MCT3 and MCT4 
seem to have crucial physiological roles21. Tumour cells 
metabolize glucose and glutamine to meet the high bio-
energetic and biosynthetic demands of continuous pro-
liferation86. As mentioned above, hypoxia and oncogenic 
mutations favour glycolysis and promote the conversion 
of pyruvate to lactate, which results in the production of 
high amounts of lactic acid86. The preferential use of lac- 
tate for oxidative metabolism involves the uptake of 
lactate by bystander, non-hypoxic tumour cells, thus 
sparing glucose for hypoxic tumour cells, which can-
not carry out oxidative metabolism5,6,86. MCTs (mainly 
MCT1) regulate the entry and exit of lactate from tumour 
cells86, and their inhibition favours the switch from lactate-
fuelled respiration to glycolysis, which consecutively kills 
hypoxic tumour cells via glucose starvation6.
Indeed, MCTs are overexpressed in many tumours, 
with MCT4 also being induced by hypoxia through 
HIF1 signalling, although this remains a controversial 
issue87. MCT inhibitors might therefore have utility as 
alternative antitumour agents, and various classes of 
such inhibitors — including DIDS, compound 25 and 
26, (FIG. 4) — are under investigation22. The efficacy of 
these inhibitors on the different MCTs varies, as well as 
their mechanisms of action22.
In a proof-of-concept study, the inhibition of 
MCT1 with compound 25 induced a switch from lactate-
fuelled respiration to glycolysis, which was accompanied 
by a retardation of tumour growth in a mouse model of 
lung carcinoma as well as in xenotransplanted human 
colorectal carcinoma cells6. This study validated MCT1 
as an antitumour target6. In another study the expression 
of MCT4 in RAS-transformed fibroblasts substantially 
increased the gradient between pHi and pHe from 0.14 to 
0.43, when compared to CCL39 wild-type tumours that 
do not express MCT4 (REF. 88). The increased pH gradients 
were paralleled by increased tumour growth and dimin-
ished necrotic regions, thus proving the important role of 
proton–lactate co-transport in tumorigenesis88. Although 
the involvement of MCTs in tumours is well estab-
lished, the lack of potent, non-toxic, isoform-selective 
MCT inhibitors has prevented further investigation of 
their potential antitumour properties. Such agents are 
urgently needed.
Current status and future prospects
TABLE 1 lists CA9 inhibitors that are in clinical develop-
ment or in use. It is worth noting that antibodies are the 
predominant agents in clinical development compared to 
small-molecule inhibitors. Apart from the splice isoforms 
of tenascin C and fibronectin (BOX 1), other proteins 
that are involved in pH regulation either still need to be 
validated as antitumour targets or their inhibitors have 
not yet reached clinical trials.
As mentioned above, two PTK inhibitors in clinical use 
— imatinib and nilotinib — also target CA2 and CA9. 
Three monoclonal antibodies — girentuximab, its radi-
olabelled variant124I-girentuximab and a CA9-specific 
auristatin antibody (BAY79-4620) — are in Phase I–III 
trials for kidney cancer, other solid tumours or as imag-
ing agents. Two small-molecule CA9 inhibitors, the sul-
phonamide U-104 and the glycosyl coumarin GC-205, 
are in advanced preclinical evaluation both for imaging 
and for the treatment of solid tumours and metastases 
in which CA9 is overexpressed47.
Several antibodies or antibody–cytokine conju-
gates targeting splice isoforms of tenascin C are also in 
Phase II–III clinical development (BOX 1). Such agents 
might be useful for the management of various cancers, 
such as brain, breast and lung cancer, as well as Hodgkin’s 
lymphomas. Several antibody–cytokine fusion products 
targeting splice isoforms of fibronectin are in Phase I–II 
clinical development for the treatment of melanoma, 
brain metastases or arthritis (BOX 1).
As outlined in this Review, the regulation of pH in 
tumours involves the interplay of many proteins, includ-
ing: carbonic anhydrases (specifically, CA9 and CA12), 
anion exchangers (AE1, AE2 and AE3), NBCs, NDCBE, 
MCTs, NHE1 and V-ATPase. Some of these proteins are 
overexpressed in tumours but their particular contribu-
tion to cancer cell proliferation is poorly understood. 
The concerted action of these proteins ensures a slightly 
alkaline pHi and an acidic pHe within the tumours, 
which favours the proliferation of the primary tumour 
and the formation of metastases. The inhibition of one 
or more of these pH regulators causes both the pHi and 
the pHe values to return to normal, with the consequent 
impairment of tumour growth. This constitutes an anti-
tumour mechanism that is not exploited by the classical 
anticancer drugs. Among these new possible antitumour 
targets, the inhibition of CA9 and CA12 with mono-
clonal antibodies or with sulphonamide- or coumarin-
based small-molecule inhibitors has been proven to 
reverse the effects of tumour acidification, leading to 
the inhibition of cancer cell growth in both primary 
tumours and metastases. This approach may be useful 
for both imaging and treating tumours that overexpress 
these two enzymes.
There are few specific, non-toxic and effective com-
pounds that interfere with the other pH-regulating 
proteins discussed in this article, but antibodies may also be 
useful for this purpose. Indeed, a polyclonal antibody that 
targets NBC3, an isoform that is mainly present in heart, 
has been reported to inhibit the cardiac electrogenic Na+/
HCO3
– co-transporter89. Similarly, antibodies that target 
the cardiac isoforms of other NBCs and AE3 (REFS 90,91) 
have been investigated. However, studies to examine their 
potential role in blocking tumour acidification have not 
yet been performed. Nevertheless, monoclonal antibodies 
may circumvent some of the toxicity and selectivity issues 
encountered with the small-molecule compounds.
R E V I E W S
NATURE REVIEWS | DRUG DISCOVERY  VOLUME 10 | OCTOBER 2011 | 775
© 2011 Macmillan Publishers Limited. All rights reserved
Some sulphonamides also seem to inhibit anion 
exchangers, whereas PPIs of the omeprazole type show 
antitumour effects — possibly by inhibiting V-ATPase. 
Potent, specific and non-toxic compounds that inhibit 
one or more of these proteins may represent valuable 
new antitumour drugs. Several antibodies, antibody–
cytokine conjugates and small molecules are currently 
in various stages of clinical development, suggesting 
that agents that interfere with pH regulation in tumours 
might soon be available in the armamentarium of anti-
tumour drugs. Combination therapies comprising such 
agents and other anticancer drugs may lead to even better 
antitumour responses, but this hypothesis warrants 
further studies.
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